WALTHAM, Mass. — November 4, 2025 — Leads & Copy —
Crescent Biopharma, Inc. (Nasdaq: CBIO) announced that preclinical data from CR-001, its PD-1 x VEGF bispecific antibody for solid tumors, will be presented at the Society for Immunotherapy of Cancer’s (SITC) 40th Annual Meeting, November 7-9, 2025, in National Harbor, Maryland.
CR-001 demonstrated cooperative pharmacology in vitro, increasing binding to PD-1 in the presence of VEGF, augmenting the PD-1/PD-L1 signaling blockade, and enhancing T-cell activation. This cooperativity was consistent with preclinical evaluation of ivonescimab, which showed superior efficacy compared to pembrolizumab in a Phase 3 trial for non-small cell lung cancer.
CR-001 also showed potent anti-tumor activity in a xenograft mouse model and was well-tolerated in non-human primates after a single intravenous dose with robust PD-1 receptor occupancy.
According to Jan Pinkas, Ph.D., chief scientific officer of Crescent, the company is on track to advance CR-001 into the clinic and plans to initiate its global Phase 1 trial in patients with solid tumors in the first quarter of 2026.
Poster presentation details:
Title: Preclinical development of CR-001, a novel tetravalent PD-1 x VEGF bispecific antibody with cooperative pharmacology and potent anti-tumor activity
Abstract Number: 1185
Presentation Date: Friday, November 7, 2025
Location: Prince George ABC Exhibit Halls, Gaylord National Resort and Convention Center
The abstract is available on SITC’s website. The poster will be available on Crescent’s website beginning at 9:00 a.m. ET on the day of the presentation.
Contact:
Amy Reilly
Chief Communications Officer
amy.reilly@crescentbiopharma.com
617-465-0586
Source: Crescent Biopharma, Inc.
